# Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

> **NCT06722664** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Healthgen Biotechnology Corp.** · enrollment: 336 (estimated)

## Conditions studied

- Gastric Mucosal Lesion

## Interventions

- **DRUG:** Recombinant Human Chymotrypsin(OsrhCT) 4000U
- **DRUG:** Placebo for Recombinant Human Chymotrypsin(OsrhCT)
- **DRUG:** Dimethicone emulsion 4ml

## Key facts

- **NCT ID:** NCT06722664
- **Lead sponsor:** Healthgen Biotechnology Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2025-05-15
- **Final completion:** 2025-05-15
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2025-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722664, "Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06722664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*